Search ... **MENU** (0,) **DONATE** Search ...



(877) 363-6376 Suite 430 Washington, DC 20036





(877) 363-6376 1615 L Street NW, Suite 430 Washington, DC 20036

**MESOTHELIOMA** \* TREATMENT AND SUPPORT \* **GET INVOLVED** ▼

> RESEARCH \* **ABOUT** • **DONATE** \*

TREATMENT AND SUPPORT \* **MESOTHELIOMA** \* **GET INVOLVED** ▼

> RESEARCH \* **ABOUT** \* **DONATE** \*

## Apply for a research grant from the Mesothelioma **Applied Research Foundation**

FOR RESEARCHERS > OBTAINING MESOTHELIOMA RESEARCH FUNDING > APPLY FOR A RESEARCH GRANT FROM THE MESOTHELIOMA APPLIED RESEARCH FOUNDATION

# 2022 Grant Cycle

Thank you for your interest in applying for a mesothelioma research grant from the Mesothelioma Applied Research Foundation for the 2022 grant cycle. Our research grant program offers \$100,000 grants for two years (\$50,000 per year).

#### **TESTIMONIALS**



- The pre-application LOI (Letter of Intent) submission period opens Friday, Oct. 14, 2022.
- The LOI deadline is at 11:59 PM ET on Monday, Nov. 21, 2022.

**Apply** 

### Who Can Apply:

- Investigators who have a doctoral-level degree and a full-time faculty position or equivalent at a college, university, medical school, or eligible not-for-profit research organization globally.
- Junior investigators with an interest in a carrier focus in mesothelioma are strongly encouraged to apply to this RFA. As part of their application, they should identify an established mesothelioma researcher as their mentor and provide a career development and mentorship plan in the context of their application.

#### Additional information to be included in the LOI:

- All applications need to focus on pleural and/or peritoneal mesothelioma and should address at least one of the 2022 Areas of Interest (listed below).
- All projects must be feasible within the timeline and budgetary constraints of the current LOI.
- All other funding, overlapping and/or supplemental funding, for the proposed project should be disclosed as part of the application.

#### Areas of Interest 2022 (not listed in order of priority):

- Novel therapies for mesothelioma for both pleural and peritoneal, especially targeted therapies, combination immunotherapy, cellular therapy, and virotherapy.
- Health-related quality of life assessment incorporating the social determinants of health (SDOH) specific to mesothelioma patient care, side effect management, mental health care impact on patient and/or caregiver outcomes, and other related topics.
- Novel strategies for screening and early detection.
- Novel strategies for risk assessment and prognosis stratification.
- Immune mediated complications of immunotherapy in mesothelioma (monitoring, early detection, and management).
- Improving personalization of therapies (gender and racial differences, targeted therapies, and predictive biomarkers).
- Mechanisms of treatment resistance/failure.
- Mesothelioma biology and etiology (disease-defining molecular pathways, cellular biology, and/or tumor microenvironment).

For questions, please contact Meghan Butler, Development Coordinator, at mbutler@curemeso.org or 703-879-3797.

Privacy Policy | Donor Privacy Policy | Copyright Notice | Site Map

1615 L Street NW, Suite 430, Washington, DC 20036 – (877) 363-



Copyright 2000-2022, Mesothelioma Applied Research Foundation – 501(c)(3) Nonprofit Organization